ArticleCancers2021

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.

Richard E Clark et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.